



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

## Statement of Standalone Unaudited Results for the Quarter ended 30 September, 2015

Particulars	(Rupees in Lakhs)					
	Quarter Ended 30-Sep-15 (Unaudited)	Quarter Ended 30-Jun-15 (Unaudited)	Quarter Ended 30-Sep-14 (Unaudited)	Year to date ended 30-Sep-15 (Unaudited)	Year to date ended 30-Sep-14 (Unaudited)	Year Ended 31-Mar-15 (Audited)
1 (a). Net Income from Sales / Services	1,277.40	1,256.56	1,508.68	2,533.93	2,922.49	4,739.44
(b). Other Operating Income	1.26	0.83	11.17	2.12	15.03	17.36
Total Income	1,278.66	1,257.39	1,519.85	2,536.05	2,937.52	4,756.80
2. Expenditure						
a) (Increase)/Decrease in Stock in Trade	-57.54	-67.28	3.89	-124.82	118.16	204.58
b) Consumption of Raw Materials	1,204.00	1,210.49	1,380.64	2,414.49	2,558.11	3,849.60
c) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	216.73
d) Employee Costs	21.25	20.25	20.08	41.50	38.87	91.20
e) Depreciation	11.09	10.84	8.89	21.94	17.54	43.76
f) Other Expenditure						
(i) Manufacturing Expenses	46.69	48.10	38.20	94.79	62.96	157.28
(ii) Administration Expenses	19.81	11.64	16.43	31.45	27.83	59.65
(iii) Selling & Distribution Expenses	20.98	8.32	11.98	29.31	24.67	44.96
g) Total	1,266.28	1,242.36	1,480.11	2,508.66	2,848.14	4,667.76
3. Profit from Operations before Other Income, Interest and Exceptional Items	12.38	15.03	39.74	27.39	89.38	89.04
4. Other Income	4.38	2.84	5.58	7.22	8.58	17.41
5. Profit before Interest and Exceptional items	16.76	17.87	45.32	34.61	97.96	106.45
6. Interest	11.91	5.88	24.78	17.78	37.03	58.55
7. Profit after Interest but before Exceptional items	4.85	11.99	20.54	16.83	60.93	47.90
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax	4.85	11.99	20.54	16.83	60.93	47.90
10. Tax expense (incl deferred tax)	-0.51	4.82	-6.32	-5.33	-22.80	16.31
11. Net Profit / (Loss) from ordinary activities after tax	4.34	7.17	14.22	11.50	38.13	31.59
12. Extraordinary Items (Nct of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	4.34	7.17	14.22	11.50	38.13	31.59
14. Paid-up Equity Share Capital (Face Value Rs. 10)	308.97	308.97	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	1,047.90	1,043.69	1,042.82	1,047.90	1,042.82	1,036.51
16. Earnings per share						
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.14	0.23	0.46	0.37	1.23	1.02
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.14	0.23	0.46	0.37	1.23	1.02
17. Public shareholding						
-- Number of shares	16,31,553	16,29,751	16,44,069	16,31,553	16,44,069	16,33,715
-- Percentage of shareholding	52.81	52.75	53.21	52.81	53.21	52.88
18. Promoters and promoter group shareholding**						
a) Pledged/ Encumbered						
-- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered						
-- Number of shares	14,58,147	14,59,949	14,45,631	14,58,147	14,45,631	14,55,985
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.19	47.25	46.79	47.19	46.79	47.12



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

## Statement of Assets & Liabilities

(Rs. in lakhs)

PARTICULARS	Standalone	
	AS ON 30-09-2015 Un-Audited	AS ON 31-03-2015 Audited
<b>EQUITY AND LIABILITIES</b>		
<b>SHAREHOLDERS' FUNDS:</b>		
(a) Share Capital	308.97	308.97
(b) Reserves And Surplus	1,047.90	1,036.51
(c) Money Received Against Share Warrants	-	-
<b>Sub total- Shareholders' Fund</b>	<b>1,356.87</b>	<b>1,345.48</b>
<b>SHARE APPLICATION MONEY PENDING ALLOTMENT</b>		
	-	-
<b>NON - CURRENT LIABILITIES</b>		
(a) Long-Term Borrowings	6.28	25.69
(b) Deferred Tax Liabilities (Net)	43.68	42.56
(c) Other Long-Term Liabilities	-	-
(d) Long-Term Provisions	-	-
<b>Sub total- Non Current Liabilities</b>	<b>49.96</b>	<b>68.25</b>
<b>CURRENT LIABILITIES</b>		
(a) Short-Term Borrowings	290.74	300.46
(b) Trade Payables	1,158.29	893.43
(c) Other Current Liabilities	1.45	19.22
(d) Short-Term Provisions	4.20	-
<b>Sub total- Current Liabilities</b>	<b>1,454.68</b>	<b>1,213.11</b>
<b>Total- Equity and Liabilities</b>	<b>2,861.51</b>	<b>2,626.84</b>
<b>ASSETS</b>		
<b>NON - CURRENT ASSETS</b>		
(a) Fixed Assets	717.03	722.13
(b) Non-Current Investment	0.10	-
(c) Deferred Tax Assets (Net)	-	-
(d) Long-Term Loans And Advances	15.28	13.10
(e) Other Non-Current Assets	45.27	41.97
<b>Sub total- Non Current Assets</b>	<b>777.68</b>	<b>777.20</b>
<b>CURRENT ASSETS</b>		
(a) Current Investment	-	-
(b) Inventories	632.88	447.23
(c) Trade Receivables	1,179.41	962.32
(d) Cash And Cash Equivalents	221.15	395.13
(e) Short Term Loans And Advances	-	2.58
(f) Other Current Assets	50.39	42.38
<b>Sub total- Current Assets</b>	<b>2,083.83</b>	<b>1,849.64</b>
<b>Total- Assets</b>	<b>2,861.51</b>	<b>2,626.84</b>

### Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 September, 2015.
- The above results have been taken on record by the Board of Directors at its Meeting held on Saturday, 14 November 2015 at the Corporate Office of the Company.
- Previous period / year's figures have been regrouped and rearranged wherever necessary.
- Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 30 September, 2015.

Opening Balance as on	1-Jul-2015	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	30-Sep-2015	0

By order of the Board of Directors  
For Samrat Pharmachem Limited

  
Lalit Mehta  
Managing Director

Place : Mumbai  
Date : 14 November 2015